Actively Recruiting
Comparison of Remifentanil with a Combination of Remimazolam and Dexmedetomidine for Awake Tracheal Intubation
Led by Nanjing First Hospital, Nanjing Medical University · Updated on 2024-09-23
60
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Awake fiberoptic intubation (AFOI) requires airway surface anesthesia to inhibit pharyngeal reflex, glottis closure reflex, and cough reflex. Additionally, the use of sedative drugs can enhance patient comfort and tolerance, reduce anxiety, and eliminate harmful effects on systemic hemodynamics.The objective of this study is to compare the safety and efficacy of remifentanil alone versus a combination of dexmedetomidine and remifentanil for sedation during conscious tracheal intubation.
CONDITIONS
Official Title
Comparison of Remifentanil with a Combination of Remimazolam and Dexmedetomidine for Awake Tracheal Intubation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients undergoing general anesthesia who require awake nasal tracheal intubation
- Age 18-65 years old
- ASA classifications of I-III
- Body mass index (BMI) less than 30 kg/m2
You will not qualify if you...
- Allergy to propofol, midazolam, dexmedetomidine, or remifentanil
- Second- or third-degree atrioventricular block, heart rate below 50 beats per minute, or systolic blood pressure below 90 mmHg
- Acute worsening of respiratory diseases such as asthma, bronchitis, or COPD
- Acute arrhythmias or severe heart diseases including congenital or valvular diseases
- Severe liver or kidney dysfunction requiring replacement therapy
- Severe mental disorders needing medication and causing communication barriers
- Moderate to severe anemia, blood clotting disorders, or blood diseases
- Basal skull fractures, facial fractures, severely deviated nasal septum, or nasal diseases causing severe congestion
- Long-term use of opioids or sedative medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nanjing First Hospital
Nanjing, Jiangsu, China, 210000
Actively Recruiting
Research Team
J
Jing Hu, MD
CONTACT
L
Lihai Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here